VIDEO: Luminate after Avastin shows early promise for treating diabetic macular edema

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Baruch D. Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at UC Irvine, discusses results from the DEL MAR trial of Luminate (Allegro) for the treatment of diabetic macular edema.

To view the video, please visit “Luminate after Avastin shows early promise for treating diabetic macular edema”

“ALG:1001: Turning Off the Machinery of Angiogenesis”

ALG-1001 (Luminate®, Allegro Ophthalmics), a first-in-class integrin peptide therapy, met the primary endpoint of vision non-inferiority to bevacizumab (Avastin, Genentech Inc.), an anti-vascular endothelial growth factor therapy (anti-VEGF), with 12-week durability in a population of patients with mostly chronic diabetic macular edema (DME).

ALG-1001 seems to be a strong player with different mechanisms of action that benefit patients who have been receiving chronic anti-VEGF therapy and those who are treatment naïve.

To read the article, please visit Ophthalmology Times“ALG-1001: Turning off the machinery of angiogenesis”

“Restoring Cell Function to Block VEGF”

Integrin peptide therapy Luminate shows potential of extending DME treatment.

Anti-VEGF drugs have proven to be effective treatments for diabetic macular edema, but about half of this population does not respond to anti-VEGF therapy and monthly injections can be burdensome. A readout from the DEL MAR Phase IIB Stage 2 clinical trial of the integrin peptide agent Luminate (Allegro Ophthalmics) as sequential therapy with anti-VEGF shows the potential of extending out those injections.

To read the article, please visit Retina Specialist“Restoring Cell Function to Block VEGF”